PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Zolmitriptan - Migraine (acute)

PAD Profile : Zolmitriptan - Migraine (acute) Important

Keywords :
Triptans, acute migraine, migraine treatment
Brand Names Include :
Zomig
Important Information :
Prescribe generically

Traffic Light Status

Status 1 of 2.

Status :
Green
Formulations :
  • Nasal spray
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
Green (see narrative)
Important
Formulations :
  • Oro-dispersible
Important Information :
Use orodispersible tablets in patients with swallowing difficulties, nausea or vomitting.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
03 May 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

GENERIC Zolmitriptan has been considered by the PCN and has been assigned a GREEN 1st line traffic light status. NOTE - the branded product, Zomig, was considered BLACK at the PCN in May 2017.

Zolmitriptan/ Rizatriptan orodispersible tablets should be considered as a suitable first line treatment for patients when there are difficulties in swallowing the solid dose formulations or the patient has difficulties with nausea and vomiting.

02 March 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
UPDATED: The PCN recommends that sumatriptan, zolmitriptan, rizatriptan and naratriptan should be considered as first line triptans where clinically appropriate and should be prescribed generically.

Associated BNF Codes

04. Central Nervous System
04.07.04. Antimigraine drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More